Physician profile
Mohammed Alsaggaf
NPI 1750816021
$3,033.84
in general payments reported to CMS, 2019-2025
23 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $587 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,811.24 |
| Education | $222.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $450.10 | 2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $370.44 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $229.35 | 2024-2025 | |
| Inspire Medical Systems, INC. | $225.40 | 2024-2025 | Inspire |
| Insmed, INC. | $189.71 | 2024-2025 | Arikayce, Brinsupri |
| Itamar Medical INC | $165.76 | 2024-2025 | Watchpatone |
| Boston Scientific Corporation | $145.42 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Viatris Specialty LLC | $141.13 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $140.78 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $139.33 | 2025 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $117.87 | 2025 | Acthar |
| Grifols USA, LLC | $111.71 | 2024-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $100.17 | 2025 | Glassia, Cuvitru |
| Harmony Biosciences LLC | $99.99 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.65 | 2024-2025 | Ofev, Jascayd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $66.80 | 2024 | Yupelri |
| Amgen INC. | $61.79 | 2025 | Tezspire |
| Electromed, INC. | $60.55 | 2024-2025 | Smartvest |
| Verona Pharma, INC. | $39.70 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $24.62 | 2025 | Zemaira |
| Ambu INC. | $23.80 | 2024 | |
| United Therapeutics Corporation | $19.53 | 2025 | Tyvaso |
| Merck Sharp & Dohme LLC | $17.24 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Alsaggaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.